Flow cytometry:ETP-ALL: Difference between revisions
From haematologyetc.co.uk
No edit summary |
No edit summary |
||
Line 26: | Line 26: | ||
<span style="font-size:90%;">3. Note that CD7 is consistently positive in ETP-ALL and does not count as a stem cell antigen in this context</span> | <span style="font-size:90%;">3. Note that CD7 is consistently positive in ETP-ALL and does not count as a stem cell antigen in this context</span> | ||
|- | |- | ||
|colspan="2" style = "font-size:90%; color:black; background:#ddeee1" |'''Requirement 2: Non-expressed antigens''' | |colspan="2" style = "font-size:90%; color:black; background:#ddeee1" | | ||
'''Requirement 2: Non-expressed antigens''' | |||
|- | |- | ||
|colspan="2" style = "font-size:90%; color:black;"|*Required absence: CD3, CD1a and CD8 (<5% of blasts) | |colspan="2" style = "font-size:90%; color:black;"|*Required absence: CD3, CD1a and CD8 (<5% of blasts) |
Revision as of 11:17, 17 January 2024
1. The immunophenotype of the blast cells should be consistent with their "primitive" nature |
The immunophenotype of ETP-ALL requires careful consideration – this reflects that the condition was identified using gene expression profiling rather than by immunophenotype. Using immunophenotype to establish the diagnosis is therefore challenging and may underestimate the number of true cases.* and may not be easily separated from ALAL T/my or T-ALL
To diagnose ETP-ALL the cells need to meet specific criteria. These are given in the table below:
Requirement 1: Expressed antigens | |
1. T-lineage should be demonstrated: (may be heterogenous but should be expressed by ≥25% of blasts)Assignment of T-Lymphoid lineage in ETP-ALL | |
Requirement 2: Non-expressed antigens | |
*Required absence: CD3, CD1a and CD8 (<5% of blasts)
| |
NOTES | |
Distinction from mixed-phenotype acute leukaemia (MPAL) requires that MPO is not expressed - in this context of ETP-ALL the WHO advocate a threshold of <3% to define negative myeloperoxidase expression (by cytochemistry or flow cytometry). This threshold is different from that of T/myeloid MPAL so may not be optimal but is retained at present.
|